Modality
ADC
MOA
MDM2i
Target
ALK
Pathway
Cell Cycle
Heart FailureNMOSD
Development Pipeline
Preclinical
~Jun 2024
→ ~Sep 2025
Phase 1
Dec 2025
→ Jun 2030
Phase 1Current
NCT08168750
1,065 pts·NMOSD
2025-12→2030-06·Active
1,065 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-164.2y awayInterim· NMOSD
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Active
Catalysts
Interim
2030-06-16 · 4.2y away
NMOSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08168750 | Phase 1 | NMOSD | Active | 1065 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| Capiglumide | BioNTech | Preclinical | CGRP |